Literature DB >> 31591123

Estimating the size of the United States market for new antibiotics with activity against carbapenem-resistant Enterobacteriaceae.

Cornelius J Clancy1, M Hong Nguyen2.   

Abstract

New antibiotics with activity against carbapenem-resistant Enterobacteriaceae (CRE) improve outcomes of CRE-infected patients. However, companies developing these drugs have faced financial difficulties. Sales of ceftazidime-avibactam, meropenem-vaborbactam and plazomicin in the United States (US) totaled $101 million from February 2018-January 2019. We estimate the current annual US market for new anti-CRE antibiotics is $289 million (range: $169-$439 million). Without new antibiotic development models and/or reimbursement reform, the majority of anti-CRE drugs will be commercially inviable.
Copyright © 2019 American Society for Microbiology.

Entities:  

Year:  2019        PMID： 31591123      PMCID： PMC6879237          DOI： 10.1128/AAC.01733-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Sustainable Discovery and Development of Antibiotics - Is a Nonprofit Approach the Future?

Authors:  Travis B Nielsen; Eric P Brass; David N Gilbert; John G Bartlett; Brad Spellberg
Journal:  N Engl J Med       Date:  2019-06-19       Impact factor: 91.245

2.  Reforming the Orphan Drug Act for the 21st Century.

Authors:  Ameet Sarpatwari; Aaron S Kesselheim
Journal:  N Engl J Med       Date:  2019-07-11       Impact factor: 91.245

3.  Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae.

Authors:  James A McKinnell; Jamie P Dwyer; George H Talbot; Lynn E Connolly; Ian Friedland; Alex Smith; Adrian M Jubb; Alisa W Serio; Kevin M Krause; George L Daikos
Journal:  N Engl J Med       Date:  2019-02-21       Impact factor: 91.245

4.  Cefiderocol: a promising antibiotic against multidrug-resistant Gram-negative bacteria.

Authors:  Shio-Shin Jean; Shun-Chung Hsueh; Wen-Sen Lee; Po-Ren Hsueh
Journal:  Expert Rev Anti Infect Ther       Date:  2019-05-06       Impact factor: 5.091

Review 5.  Economic Incentives for Antibacterial Drug Development: Literature Review and Considerations From the Transatlantic Task Force on Antimicrobial Resistance.

Authors:  Kimberly Sciarretta; John-Arne Røttingen; Aleksandra Opalska; Arjon J Van Hengel; Joseph Larsen
Journal:  Clin Infect Dis       Date:  2016-08-30       Impact factor: 9.079

6.  Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.

Authors:  Ryan K Shields; Brian A Potoski; Ghady Haidar; Binghua Hao; Yohei Doi; Liang Chen; Ellen G Press; Barry N Kreiswirth; Cornelius J Clancy; M Hong Nguyen
Journal:  Clin Infect Dis       Date:  2016-09-13       Impact factor: 9.079

7.  Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.

Authors:  Evelina Tacconelli; Elena Carrara; Alessia Savoldi; Stephan Harbarth; Marc Mendelson; Dominique L Monnet; Céline Pulcini; Gunnar Kahlmeter; Jan Kluytmans; Yehuda Carmeli; Marc Ouellette; Kevin Outterson; Jean Patel; Marco Cavaleri; Edward M Cox; Chris R Houchens; M Lindsay Grayson; Paul Hansen; Nalini Singh; Ursula Theuretzbacher; Nicola Magrini
Journal:  Lancet Infect Dis       Date:  2017-12-21       Impact factor: 71.421

8.  What Is the Purpose of the Orphan Drug Act?

Authors:  Matthew Herder
Journal:  PLoS Med       Date:  2017-01-03       Impact factor: 11.069

9.  Estimating the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in the United States Using Antibiotic Prescription Data.

Authors:  Cornelius J Clancy; Brian A Potoski; Deanna Buehrle; M Hong Nguyen
Journal:  Open Forum Infect Dis       Date:  2019-07-28       Impact factor: 3.835

Review 10.  Progress in the Fight Against Multidrug-Resistant Bacteria 2005-2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance.

Authors:  John H Rex; George H Talbot; Mark J Goldberger; Barry I Eisenstein; Roger M Echols; John F Tomayko; Michael N Dudley; Aaron Dane
Journal:  Clin Infect Dis       Date:  2017-07-01       Impact factor: 9.079
View more
  5 in total

1.  The Economic Conundrum for Antibacterial Drugs.

Authors:  David M Shlaes
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

2.  Prospects for Antibacterial Discovery and Development.

Authors:  Thomas M Privalsky; Alexander M Soohoo; Jinhua Wang; Christopher T Walsh; Gerard D Wright; Eric M Gordon; Nathanael S Gray; Chaitan Khosla
Journal:  J Am Chem Soc       Date:  2021-12-03       Impact factor: 15.419

Review 3.  Filamentous Thermosensitive Mutant Z: An Appealing Target for Emerging Pathogens and a Trek on Its Natural Inhibitors.

Authors:  Manisha Gurnani; Abhishek Chauhan; Anuj Ranjan; Hardeep Singh Tuli; Mustfa F Alkhanani; Shafiul Haque; Kuldeep Dhama; Rup Lal; Tanu Jindal
Journal:  Biology (Basel)       Date:  2022-04-20

Review 4.  Metallo-β-Lactamase Inhibitors Inspired on Snapshots from the Catalytic Mechanism.

Authors:  Antonella R Palacios; María-Agustina Rossi; Graciela S Mahler; Alejandro J Vila
Journal:  Biomolecules       Date:  2020-06-03

5.  Needs assessment for novel Gram-negative antibiotics in US hospitals: a retrospective cohort study.

Authors:  Jeffrey R Strich; Sarah Warner; Yi Ling Lai; Cumhur Y Demirkale; John H Powers; Robert L Danner; Sameer S Kadri
Journal:  Lancet Infect Dis       Date:  2020-06-04       Impact factor: 71.421
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.